These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 11565214)

  • 1. Torsade de pointes induced by ajmaline.
    Haverkamp W; Mönnig G; Kirchhof P; Eckardt L; Borggrefe M; Breithardt G
    Z Kardiol; 2001 Aug; 90(8):586-90. PubMed ID: 11565214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ibutilide-induced long QT syndrome and torsade de pointes.
    Gowda RM; Punukollu G; Khan IA; Patlola RR; Tejani FH; Cosme-Thormann BF; Vasavada BC; Sacchi TJ
    Am J Ther; 2002; 9(6):527-9. PubMed ID: 12424513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [QT prolongation and torsade de pointes tachycardia during therapy with maprotiline. Differential diagnostic and therapeutic aspects].
    Lentini S; Rao ML; Schröder R; Lüderitz B; Bauriedel G
    Dtsch Med Wochenschr; 2001 Dec; 126(49):1396-400. PubMed ID: 11740632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dofetilide induced torsade de pointes: mechanism, risk factors and management strategies.
    Jaiswal A; Goldbarg S
    Indian Heart J; 2014; 66(6):640-8. PubMed ID: 25634399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dofetilide-induced long QT and torsades de pointes.
    Aktas MK; Shah AH; Akiyama T
    Ann Noninvasive Electrocardiol; 2007 Jul; 12(3):197-202. PubMed ID: 17617063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Precordial QT interval dispersion as a marker of torsade de pointes. Disparate effects of class Ia antiarrhythmic drugs and amiodarone.
    Hii JT; Wyse DG; Gillis AM; Duff HJ; Solylo MA; Mitchell LB
    Circulation; 1992 Nov; 86(5):1376-82. PubMed ID: 1423949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-induced torsade de pointes. Incidence, management and prevention.
    Faber TS; Zehender M; Just H
    Drug Saf; 1994 Dec; 11(6):463-76. PubMed ID: 7727055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiarrhythmic drugs and torsade de pointes.
    Lazzara R
    Eur Heart J; 1993 Nov; 14 Suppl H():88-92. PubMed ID: 8293758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [QTc-prolonging drugs and the risk of sudden death].
    Reingardiene D; Vilcinskaite J
    Medicina (Kaunas); 2007; 43(4):347-53. PubMed ID: 17485963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amiodarone in patients with previous drug-mediated torsade de pointes. Long-term safety and efficacy.
    Mattioni TA; Zheutlin TA; Sarmiento JJ; Parker M; Lesch M; Kehoe RF
    Ann Intern Med; 1989 Oct; 111(7):574-80. PubMed ID: 2774388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. QT prolongation and development of torsades de pointes with the concomitant administration of oral erythromycin base and quinidine.
    Lin JC; Quasny HA
    Pharmacotherapy; 1997; 17(3):626-30. PubMed ID: 9165570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Electrocardiographic and clinical predictors of torsades de pointes induced by almokalant infusion in patients with chronic atrial fibrillation or flutter: a prospective study.
    Houltz B; Darpö B; Edvardsson N; Blomström P; Brachmann J; Crijns HJ; Jensen SM; Svernhage E; Vallin H; Swedberg K
    Pacing Clin Electrophysiol; 1998 May; 21(5):1044-57. PubMed ID: 9604236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluconazole-associated QT interval prolongation and Torsades de Pointes in a paediatric patient.
    Ünal Yüksekgönül A; Ertuğrul İ; Karagöz T
    Cardiol Young; 2021 Dec; 31(12):2035-2037. PubMed ID: 34024302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
    Lu HR; Yan GX; Gallacher DJ
    J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac safety, drug-induced QT prolongation and torsade de pointes (TdP).
    Ritter JM
    Br J Clin Pharmacol; 2012 Mar; 73(3):331-4. PubMed ID: 22329611
    [No Abstract]   [Full Text] [Related]  

  • 16. Drugs, QT interval abnormalities and ventricular arrhythmias.
    Thomas SH
    Adverse Drug React Toxicol Rev; 1994; 13(2):77-102. PubMed ID: 7918900
    [No Abstract]   [Full Text] [Related]  

  • 17. Chemical cardioversion of atrial fibrillation or flutter with ibutilide in patients receiving amiodarone therapy.
    Glatter K; Yang Y; Chatterjee K; Modin G; Cheng J; Kayser S; Scheinman MM
    Circulation; 2001 Jan; 103(2):253-7. PubMed ID: 11208685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reckless administration of QT interval-prolonging agents in elderly patients with drug-induced torsade de pointes.
    Jackobson G; Carmel NN; Lotan D; Kremer A; Justo D
    Z Gerontol Geriatr; 2018 Jan; 51(1):41-47. PubMed ID: 27878411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amiodarone induced torsades de pointes with excessive QT dispersion following quinidine induced polymorphic ventricular tachycardia.
    Tran HT; Chow MS; Kluger J
    Pacing Clin Electrophysiol; 1997 Sep; 20(9 Pt 1):2275-8. PubMed ID: 9309756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and proarrhythmia with the use of d,l-sotalol for sustained ventricular tachyarrhythmias.
    Kühlkamp V; Mermi J; Mewis C; Seipel L
    J Cardiovasc Pharmacol; 1997 Mar; 29(3):373-81. PubMed ID: 9125676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.